Sharon Townson
Fortuna: 2 M $ al 30/06/2026
Fortuna: 2 M $ al 30/06/2026
Dr. Sharon Townson is a Chief Scientific Officer at Monte Rosa Therapeutics, Inc. Dr. Townson was previously employed as an Executive Director & Head-Platform Biology by Kymera Therapeutics, Inc. and a Scientific Director-Physical Biochemistry by Warp Drive Bio, Inc. She received her undergraduate degree from the University of Salford and a doctorate degree from the University of Manchester Institute of Science & Technology.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 06/07/2026 | 67.845 ( 0,08 % ) | 2 M $ | 30/06/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| MONTE ROSA THERAPEUTICS, INC. | Director Técnico/Científico/I+D | 01/01/2021 |
| Empresas | Cargo | Fin |
|---|---|---|
| KYMERA THERAPEUTICS, INC. | Director/Miembro de la Junta | 01/06/2020 |
Warp Drive Bio, Inc.
Warp Drive Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Focuses on proprietary genomic technology to discover drugs of natural origin | Corporate Officer/Principal | 01/12/2018 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 5 |
|---|---|
University of Salford
University of Salford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Manchester Institute of Science & Technology
University of Manchester Institute of Science & Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Warp Drive Bio, Inc.
Warp Drive Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Focuses on proprietary genomic technology to discover drugs of natural origin | Commercial Services |
Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops immunology medicines for health problems | Health Technology |
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops molecular glue degrader medicines for oncology, autoimmune and inflammatory diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.